Search results for "recombinant"

showing 10 items of 1150 documents

IL-6 receptor independent stimulation of human gp130 by viral IL-6.

2000

Abstract The genome of human herpes virus 8, which is associated with Kaposi’s sarcoma, encodes proteins with similarities to cytokines and chemokines including a homologue of IL-6. Although the function of these viral proteins is unclear, they might have the potential to modulate the immune system. For viral IL-6 (vIL-6), it has been demonstrated that it stimulates IL-6-dependent cells, indicating that the IL-6R system is used. IL-6 binds to IL-6R, and the IL-6/IL-6R complex associates with gp130 which dimerizes and initiates intracellular signaling. Cells that only express gp130 but no IL-6R cannot be stimulated by IL-6 unless a soluble form of the IL-6R is present. This type of signaling…

MaleSTAT3 Transcription FactorChemokinemedicine.medical_treatmentImmunologyGenetic VectorsBiologylaw.inventionViral ProteinsImmune systemlawAntigens CDmedicineCytokine Receptor gp130Tumor Cells CulturedImmunology and AllergyAnimalsChemical PrecipitationHumansCloning MolecularPhosphorylationInterleukin 6Sarcoma KaposiAgedMembrane GlycoproteinsInterleukin-6Glycoprotein 130Receptors Interleukin-6Growth InhibitorsRecombinant ProteinsCell biologyDNA-Binding ProteinsCytokineInterleukin-6 receptorCOS CellsRecombinant DNAbiology.proteinTrans-ActivatorsIntracellularProtein BindingSignal TransductionJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

2015

Summary The aim of this study was to elucidate more clearly the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjögren's syndrome (pSS) patients and in pSS-associated lymphomas. Minor salivary glands (MSGs) from patients with pSS and non-specific chronic sialoadenitis (nSCS), parotid glands biopsies from non-Hodgkin lymphomas (NHL) developed in pSS patients, were evaluated for IL-18, IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and signal transducer and activator of transcription-3 (STAT-3) expression. MSGs IL-22R1-expressing cells were characterized by confocal microscopy and flow cytometry in pSS, nSCS and healthy controls. The effect of recom…

MaleSalivary Glandslaw.inventionInterleukin 22lawIL-22Immunology and AllergyMyeloid CellsIL-22R1Receptormedicine.diagnostic_testnon-Hodgkin lymphomaLymphoma Non-HodgkinInterleukin-17TranslationalInterleukin-18Lacrimal ApparatusInterleukinMiddle AgedHaematopoiesisSjogren's SyndromeIL-22BPRecombinant DNASjögren's syndromeInterleukin 18FemaleIL-18Signal TransductionAdultSTAT3 Transcription FactorImmunologyPrimary Cell CultureBiologyPeripheral blood mononuclear cellIL-18; IL-22; IL-22BP; IL-22R1; Sjögren's syndrome; non-Hodgkin lymphomaSialadenitisFlow cytometrystomatognathic systemmedicineHumansAgedInterleukinsMacrophagesReceptors InterleukinSettore MED/16 - Reumatologiastomatognathic diseasesGene Expression RegulationImmunologyLeukocytes MononuclearClinical and experimental immunology
researchProduct

Genetic feminization of pheromones and its behavioral consequences in Drosophila males

1997

0036-8075 (Print) Journal Article Research Support, Non-U.S. Gov't; Pheromones are intraspecific chemical signals important for mate attraction and discrimination. In the fruit fly Drosophila melanogaster, hydrocarbons on the cuticular surface of the animal are sexually dimorphic in both their occurrence and their effects: Female-specific molecules stimulate male sexual excitation, whereas the predominant male-specific molecule tends to inhibit male excitation. Complete feminization of the pheromone mixture produced by males was induced by targeted expression of the transformer gene in adult oenocytes (subcuticular abdominal cells) or by ubiquitous expression during early imaginal life. The…

MaleSex CharacteristicsSex DifferentiationRecombinant Fusion ProteinsSexual BehaviorfungiHomosexualityNuclear Proteins/genetics/physiologyDrosophila melanogasterGene Expression RegulationAnimal/physiologyAnimalsSex Attractants/genetics/*physiologyFemaleDevelopmentalTransgenes
researchProduct

Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C

2007

OBJECTIVES: The aims of this study were to investigate the expression of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) in chronic hepatitis C (CHC) by immunohistochemistry, based on the hypothesis that COXs expression could vary according to genotype, viral load, liver steatosis, BMI and response to therapy and to determine whether the addition of selective COX inhibitors could have a rationale in increasing the efficacy of antiviral therapy. METHODS: We used 35 formalin-fixed, paraffin-embedded liver tissue samples obtained by needle biopsy from patients with CHC (17F/18M) with one of two types of genotype (1b and 3a). The presence of COX-1 and COX-2 in the cytoplasm of hepatocyt…

MaleSteatosisGene ExpressionHepacivirusChronic hepatitis CGastroenterologychemistry.chemical_compoundmedicine.diagnostic_testFatty liverGastroenterologyMiddle AgedImmunohistochemistryRecombinant ProteinsCyclooxygenaseTreatment OutcomeLiverRNA ViralFemaleViral loadmedicine.drugAdultmedicine.medical_specialtyAdolescentGenotypeCombination therapyAlpha interferonInterferon alpha-2Antiviral AgentsInternal medicineRibavirinBiopsymedicineHumansInterferon alfaAgedStaining and LabelingHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C AntibodiesHepatitis C Chronicmedicine.diseasechemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesImmunologyCyclooxygenase 1SteatosisbusinessInterferon-αEuropean Journal of Gastroenterology & Hepatology
researchProduct

HIF-1α and Pro-Inflammatory Signaling Improves the Immunomodulatory Activity of MSC-Derived Extracellular Vesicles

2021

Despite the strong evidence for the immunomodulatory activity of mesenchymal stromal cells (MSCs), clinical trials have so far failed to clearly show benefit, likely reflecting methodological shortcomings and lack of standardization. MSC-mediated tissue repair is commonly believed to occur in a paracrine manner, and it has been stated that extracellular vesicles (EVs) secreted by MSCs (EVMSC) are able to recapitulate the immunosuppressive properties of parental cells. As a next step, clinical trials to corroborate preclinical studies should be performed. However, effective dose in large mammals, including humans, is quite high and EVs industrial production is hindered by the proliferative s…

MaleT-Lymphocytesmedicine.medical_treatmentCellimmunomodulationProtein Engineeringlcsh:ChemistryMiceHypersensitivity Delayedlcsh:QH301-705.5TelomeraseCells CulturedSpectroscopyMice Inbred BALB CGeneral MedicineRecombinant ProteinsComputer Science ApplicationsCell biologyCytokinemedicine.anatomical_structurehypoxia-inducible factor 1-alphaCytokinesmesenchymal stromal cellsGenetic VectorsGreen Fluorescent ProteinsBiologyMesenchymal Stem Cell TransplantationArticleCatalysisCell LineViral vectorInorganic ChemistryExtracellular VesiclesYoung AdultParacrine signallingIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyDental PulpCell ProliferationT-cellsLentivirusOrganic ChemistryMesenchymal stem cellMesenchymal Stem CellsHypoxia-Inducible Factor 1 alpha SubunitIn vitrolcsh:Biology (General)lcsh:QD1-999Cell cultureInternational Journal of Molecular Sciences
researchProduct

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.

2018

Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered. Methods The effects of blocking activin receptor type 2 (ACVR2) ligands on both muscle and non‐muscle tissues were investigated in a preclinical model of cancer cachexia using a recombinant soluble ACVR2B (sACVR2B‐Fc). Treatment with sACVR2B‐Fc was applied either only before the tumour formation or with continued treatment both before and after tumour formation. The potential roles of muscle and non‐muscle tissues in cancer cachexia were investigated in order to understand th…

MaleTUMOR-BEARING MICElcsh:Diseases of the musculoskeletal systemCachexiaprotein synthesisActivin Receptors Type IIMDSCphysical activityAcute phase responseKaplan-Meier EstimateACTIVATIONActivinMiceNeoplasmsOrthopedics and Sports MedicineTOR Serine-Threonine Kinasesactivinlcsh:Human anatomyII RECEPTORSRecombinant ProteinsProtein TransportLivermyostatinPROTEIN-SYNTHESISSKELETAL-MUSCLECytokinessyöpätauditInflammation MediatorsACUTE-PHASE RESPONSE3122 CancersINHIBITIONlcsh:QM1-695acute phase responsePhysiology (medical)Cell Line TumorAnimalsHumansMuscle SkeletalActivin; Acute phase response; MDSC; Myostatin; Physical activity; Protein synthesis; Orthopedics and Sports Medicine; Physiology (medical)Physical activityMyeloid-Derived Suppressor CellsMyostatinXenograft Model Antitumor AssaysDisease Models AnimalACTIVIN-APHYSICAL-ACTIVITY3121 General medicine internal medicine and other clinical medicineproteiinitEXPERIMENTAL CANCER CACHEXIAlcsh:RC925-935Protein synthesislihassurkastumasairaudetBiomarkersSpleenJournal of cachexia, sarcopenia and muscle
researchProduct

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with H…

2016


 
 
 
 
 
 Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on hepatitis C virus antiviral therapy.
 Methods: Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed.
 Resu…

MaleTime Factors030508 substance abuseHepacivirusmedicine.disease_causeGastroenterologyTelaprevirPolyethylene Glycolschemistry.chemical_compound0302 clinical medicineRisk FactorsGermanyOdds RatioAged 80 and overSmokingGastroenterologyHepatitis CMiddle AgedViral LoadHepatitis CRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemale0305 other medical scienceViral loadOligopeptidesmedicine.drugAdultmedicine.medical_specialtyAdolescentGenotypeProlineHepatitis C virusAlpha interferonAntiviral Agents03 medical and health sciencesYoung AdultBoceprevirInternal medicineRibavirinmedicineHumansProtease inhibitor (pharmacology)Protease InhibitorsAgedbusiness.industryRibavirinInterferon-alphamedicine.diseaseVirology030227 psychiatryLogistic ModelschemistryMultivariate AnalysisbusinessJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Neuroprotection by erythropoietin administration after experimental traumatic brain injury.

2007

A large body of evidence indicates that the hormone erythropoietin (EPO) exerts beneficial effects in the central nervous system (CNS). To date, EPO's effect has been assessed in several experimental models of brain and spinal cord injury. This study was conducted to validate whether treatment with recombinant human EPO (rHuEPO) would limit the extent of injury following experimental TBI. Experimental TBI was induced in rats by a cryogenic injury model. rHuEPO or placebo was injected intraperitoneally immediately after the injury and then every 8 h until 2 or 14 days. Forty-eight hours after injury brain water content, an indicator of brain edema, was measured with the wet-dry method and bl…

MaleTime FactorsBrain EdemaFunctional LateralityRats Sprague-Dawleychemistry.chemical_compoundTraumatic brain injuryMedicineAnalysis of Variance Animals Blood-Brain Barrier; drug effects Brain Edema; drug therapy/etiology Brain Infarction; drug therapy/etiology Brain Injuries; complications/drug therapy Disease Models; Animal Erythropoietin; administration /&/ dosage Evans Blue; diagnostic use Functional Laterality Humans Male Neurologic Examination Neuroprotective Agents; administration /&/ dosage Rats Rats; Sprague-Dawley Reaction Time; drug effects Recombinant Proteins Time Factorsadministration /&/ dosageSpinal cord injuryEvans BlueNeurologic ExaminationGeneral Neuroscienceexperimental models of brain and spinal cord injuryExtravasationNeuroprotectionRecombinant Proteinsmedicine.anatomical_structureNeuroprotective AgentsBlood-Brain BarrierAnesthesiadiagnostic usemedicine.drugEvans BlueBrain InfarctionTraumatic brain injuryCentral nervous systemrecombinant human EPO (rHuEPO)PlaceboNeuroprotectionReaction TimeAnimalsHumansMolecular BiologyErythropoietinAnalysis of VarianceNeuroscience (all)business.industryAnimaldrug therapy/etiologymedicine.diseaseRatsDisease Models AnimalchemistryErythropoietindrug effectsBrain InjuriesDisease Modelsrecombinant human EPO (rHuEPO); experimental models of brain and spinal cord injury; NeuroprotectionNeurology (clinical)Sprague-Dawleybusinesscomplications/drug therapyDevelopmental BiologyBrain research
researchProduct

Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury. Laboratory investigation.

2007

Object The objectives of this study were to examine whether the systemic administration of recombinant human erythropoietin (rHuEPO) and its long-lasting derivative darbepoetin alfa expedited functional recovery in a rat model of sciatic nerve injury, and to compare the effects of these agents in the model. Methods Thirty male Sprague–Dawley rats received a crush injury to the left sciatic nerve and subsequently underwent either placebo treatment, daily injections of rHuEPO, or weekly injections of darbepoetin alfa. Results Both rHuEPO and darbepoetin alfa were effective in reducing neurological impairment and improving compound muscle action potentials following nerve injury. Darbepoetin …

MaleTime FactorsDarbepoetin alfaNerve CrushAction PotentialsPlaceboDrug Administration ScheduleRats Sprague-Dawleyadministration /&/ dosage/pharmacologymedicineAnimalsHumansDarbepoetin alfaMuscle SkeletalErythropoietinERYTHROPOIETINdrug effects/injuries/physiopathologySettore MED/27 - Neurochirurgiabusiness.industryAction Potentials; drug effects Animals Drug Administration Schedule Erythropoietin; administration /&/ dosage/analogs /&/ derivatives/pharmacology Humans Male Muscle; Skeletal; physiopathology Nerve Crush Neuroprotective Agents; administration /&/ dosage/pharmacology Rats Rats; Sprague-Dawley Recombinant Proteins Recovery of Function; drug effects Sciatic Nerve; drug effects/injuries/physiopathology Time FactorsGeneral MedicineSkeletalRecovery of FunctionNerve injurySciatic nerve injurymedicine.diseaseadministration /&/ dosage/analogs /&/ derivatives/pharmacologySciatic NerveNeuroprotectionRecombinant ProteinsRatsNeuroprotective AgentsNeurologyErythropoietinPeripheral nerve injuryAnesthesiadrug effectsPeripheral nerve injuryCrush injuryMuscleSurgeryNeurology (clinical)Sciatic nerveSprague-Dawleymedicine.symptomphysiopathologybusinessmedicine.drug
researchProduct

The time course of recombinant production in Streptomyces coelicolor.

1971

SUMMARYThe process leading to gene recombination can be interrupted in the filamentous bacteriaStreptomyces coelicolorby growing mixed cultures on cellophane disks lying on complete medium. The mycelium is harvested, broken, diluted and the broken hyphae plated at different time intervals. By this means some markers can be excluded from heteroclones or from recombinant progeny in early samples. The recombinant pattern clearly changes with time, with an increase of markers contributed to the recombinant progeny. In crosses between male (NF) and female (UF) strains, the maleness is the first donor trait to appear in the cells of the recipient parent. The fertility factor does not produce a tr…

MaleTime FactorsHyphaBiologyGenetic recombinationlaw.inventionlawGeneticsMyceliumCrosses GeneticInfertility MaleRecombination GeneticSpores BacterialFertility factor (bacteria)fungiStreptomyces coelicolorChromosomeChromosome MappingGeneral MedicineChromosomes Bacterialbiology.organism_classificationMolecular biologyStreptomycesSporePhenotypeConjugation GeneticMutationRecombinant DNAGenetical research
researchProduct